CRSP
Price
$52.17
Change
+$0.50 (+0.97%)
Updated
Jul 3 closing price
Capitalization
4.51B
36 days until earnings call
YMAB
Price
$4.30
Change
+$0.04 (+0.94%)
Updated
Jul 3 closing price
Capitalization
194.77M
33 days until earnings call
Interact to see
Advertisement

CRSP vs YMAB

Header iconCRSP vs YMAB Comparison
Open Charts CRSP vs YMABBanner chart's image
CRISPR Therapeutics AG
Price$52.17
Change+$0.50 (+0.97%)
Volume$1.84M
Capitalization4.51B
Y-mAbs Therapeutics
Price$4.30
Change+$0.04 (+0.94%)
Volume$81.29K
Capitalization194.77M
CRSP vs YMAB Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. YMAB commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and YMAB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (CRSP: $52.17 vs. YMAB: $4.30)
Brand notoriety: CRSP and YMAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 68% vs. YMAB: 40%
Market capitalization -- CRSP: $4.51B vs. YMAB: $194.77M
CRSP [@Biotechnology] is valued at $4.51B. YMAB’s [@Biotechnology] market capitalization is $194.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileYMAB’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • YMAB’s FA Score: 1 green, 4 red.
According to our system of comparison, both CRSP and YMAB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 5 TA indicator(s) are bullish while YMAB’s TA Score has 4 bullish TA indicator(s).

  • CRSP’s TA Score: 5 bullish, 4 bearish.
  • YMAB’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CRSP is a better buy in the short-term than YMAB.

Price Growth

CRSP (@Biotechnology) experienced а +11.71% price change this week, while YMAB (@Biotechnology) price change was -10.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

CRSP is expected to report earnings on Oct 29, 2025.

YMAB is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.51B) has a higher market cap than YMAB($195M). CRSP YTD gains are higher at: 32.546 vs. YMAB (-45.083). YMAB has higher annual earnings (EBITDA): -30.39M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. YMAB (60.3M). YMAB has less debt than CRSP: YMAB (603K) vs CRSP (219M). YMAB has higher revenues than CRSP: YMAB (88.7M) vs CRSP (35M).
CRSPYMABCRSP / YMAB
Capitalization4.51B195M2,311%
EBITDA-455.24M-30.39M1,498%
Gain YTD32.546-45.083-72%
P/E RatioN/AN/A-
Revenue35M88.7M39%
Total Cash1.86B60.3M3,076%
Total Debt219M603K36,318%
FUNDAMENTALS RATINGS
CRSP vs YMAB: Fundamental Ratings
CRSP
YMAB
OUTLOOK RATING
1..100
5065
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
30
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
3889
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YMAB's Valuation (30) in the Pharmaceuticals Major industry is somewhat better than the same rating for CRSP (67) in the Biotechnology industry. This means that YMAB’s stock grew somewhat faster than CRSP’s over the last 12 months.

YMAB's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CRSP (100) in the Biotechnology industry. This means that YMAB’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as YMAB (96) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to YMAB’s over the last 12 months.

CRSP's Price Growth Rating (38) in the Biotechnology industry is somewhat better than the same rating for YMAB (89) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew somewhat faster than YMAB’s over the last 12 months.

CRSP's P/E Growth Rating (81) in the Biotechnology industry is in the same range as YMAB (100) in the Pharmaceuticals Major industry. This means that CRSP’s stock grew similarly to YMAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPYMAB
RSI
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
61%
Bearish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 12 days ago
81%
Declines
ODDS (%)
Bearish Trend 24 days ago
84%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
81%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
YMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PMBMX43.650.45
+1.04%
Principal MidCap R3
CVTRX52.330.47
+0.91%
Calamos Growth & Income A
JSVSX15.300.09
+0.59%
Janus Henderson Small-Mid Cap Value S
HFDYX19.430.11
+0.57%
Hartford Schroders US MidCap Opps Y
MDDLX10.450.05
+0.48%
MassMutual Diversified Value Adm

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+0.97%
RXRX - CRSP
72%
Closely correlated
+1.15%
BEAM - CRSP
72%
Closely correlated
+0.65%
NTLA - CRSP
66%
Loosely correlated
+0.09%
PRME - CRSP
64%
Loosely correlated
+1.30%
CRBU - CRSP
63%
Loosely correlated
N/A
More

YMAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with ARWR. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then ARWR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YMAB
1D Price
Change %
YMAB100%
+0.94%
ARWR - YMAB
52%
Loosely correlated
-0.65%
OCUL - YMAB
50%
Loosely correlated
+1.69%
CRSP - YMAB
49%
Loosely correlated
+0.97%
FATE - YMAB
48%
Loosely correlated
N/A
IPSC - YMAB
47%
Loosely correlated
+0.02%
More